GenBio - Genome Biologics: Our Technology - Vdeo
Modern drug discovery is inefficient, expensive and risky. On average, there are 2000 failed compounds sitting on pharmaceutical companies shelves, and this number grows at the rate 200 drugs per year. Furthermore, the average costs of a successful drug introduction is a staggering $3bln with an average time-to-market of more than 10 years. This is due to extensive discovery costs including: R&D, laboratory and animal testing, toxicology and clinical trials and market approval. Due to high development costs, diseases with smaller market share, such as rare diseases are only satisfied in 5% of cases leaving nearly 350mln people worldwide without any treatments.
The Genome Biologics GENIMAPS® and GENISYST® patented drug discovery and testing platform overcomes the inefficiencies of pre-clinical studies with its unique combination of genomics, molecular science and. Using our proprietary Artificial Intelligence-driven Drug-Disease matching platform GENIMAPS® and our patented single cell transgenic technology GENISYST®, the platform reduces drug development or drug repurposing time and costs by a factor of 10, allowing pharmaceuticals companies to bring drug candidates into phase 2-3 clinical trials in as little as 3-6 months, instead of 7-10 years with current methodologies.
This technology was developed with funding from the European Union (EU) H2020 SME instrument.
The Genome Biologics GENIMAPS® and GENISYST® patented drug discovery and testing platform overcomes the inefficiencies of pre-clinical studies with its unique combination of genomics, molecular science and. Using our proprietary Artificial Intelligence-driven Drug-Disease matching platform GENIMAPS® and our patented single cell transgenic technology GENISYST®, the platform reduces drug development or drug repurposing time and costs by a factor of 10, allowing pharmaceuticals companies to bring drug candidates into phase 2-3 clinical trials in as little as 3-6 months, instead of 7-10 years with current methodologies.
This technology was developed with funding from the European Union (EU) H2020 SME instrument.
-
Most popular related searches
Customer comments
No comments were found for GenBio - Genome Biologics: Our Technology - Vdeo. Be the first to comment!